Home・Akciju saraksts・Zoetis Inc

Zoetis Inc

Slēgts

SektorsVeselības aprūpe

75.98 -1.43

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

76.83

Max

79.78

Galvenie mērījumi
By Trading Economics
Ienākumi	-2M 601M
Pārdošana	-125M 2.3B
P/E Sektora vidējais	12.61 64.641
EPS	1.53
Dividenžu ienesīgums	2.69
Peļņas marža	26.569
Darbinieki	14,500
EBITDA	-8M 939M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+28.58% upside

Dividendes
By Acuity
Dividenžu ienesīgums Sektora vidējais	2.69% 2.31%
Nākamie ieņēmumi	2026. g. 6. aug.
Nākamais dividenžu datums	2026. g. 1. sept.
Nākamais Ex dividenžu datums	2026. g. 30. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-16B 32B
Iepriekšējā atvēršanas cena	77.41
Iepriekšējā slēgšanas cena	75.98

Ziņu noskaņojums

By Acuity

43%

57%

135 / 340 Rangs Healthcare

Zoetis Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 23:31 UTC

Zoetis Inc shares are higher in after-market trading, continuing positive momentum after three consecutive sessions of gains amid favorable market sentiment.

2026. g. 1. aug. 00:01 UTC

Zoetis Inc shares rose in after-market trading, recovering from an initial dip and reaching a high near the upper end of its one-month range.

2026. g. 31. jūl. 23:06 UTC

Zoetis Inc shares are higher in after-market trading, maintaining gains since Friday's close and remaining above the 20-day moving average.

2026. g. 30. jūl. 19:03 UTC

Zoetis Inc shares are lower, impacted by a decline in the Pharmaceuticals sub-sector. Earlier in the session, the stock peaked before falling.

2026. g. 29. jūl. 22:51 UTC

Zoetis Inc shares are trading lower in after-market hours. No specific news was identified to explain the decline amid broader market volatility.

2026. g. 28. jūl. 23:02 UTC

Zoetis Inc shares are higher in after-market trading, reflecting broader market strength amid investor optimism ahead of key earnings reports and the Federal Reserve meeting.

2026. g. 27. jūl. 23:16 UTC

News

Zoetis shares are lower in after-market hours following a class action lawsuit alleging securities fraud and reduced profit guidance to between $6.85 and $7.00 per share.

2026. g. 25. jūl. 00:01 UTC

Zoetis Inc. shares are trading higher in after-market hours, continuing a positive trend after closing higher for three consecutive sessions.

2026. g. 24. jūl. 21:02 UTC

Zoetis Inc shares are higher in after-market trading, rebounding from an initial dip despite a broader market decline influenced by disappointing earnings from Tesla and Alphabet.

2026. g. 23. jūl. 20:02 UTC

Zoetis Inc. shares are higher as strength in the pharmaceuticals sub-sector drives upward momentum, contributing to modest gains since Wednesday's close.

2026. g. 22. jūl. 21:02 UTC

Zoetis Inc. shares are lower in after-market trading, continuing a trend of five consecutive daily declines amid mixed market performance and rising crude oil prices.

2026. g. 21. jūl. 17:51 UTC

News

Zoetis Inc. shares are lower amid scrutiny from a securities fraud class action lawsuit alleging undisclosed market share declines and safety issues with Librela.

2026. g. 20. jūl. 23:16 UTC

Zoetis shares traded higher in after-market hours, maintaining stability above Monday's close despite broader market pressures from rising treasury yields.

Salīdzinājums

Cenas izmaiņa

Zoetis Inc Prognoze

Cenas mērķis

By TipRanks

28.58% augšup

Prognoze 12 mēnešiem

Vidējais 99.38 USD 28.58%

Augstākais 130 USD

Zemākais 85 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zoetis Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zoetis Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

135 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zoetis Inc

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.